Salmonella Typhimurium enolase-like membrane protein is recognized by antibodies against human enolase and interacts with plasminogen.


Journal

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
ISSN: 1899-5276
Titre abrégé: Adv Clin Exp Med
Pays: Poland
ID NLM: 101138582

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 28 11 2020
medline: 7 2 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

Enolase is generally known as the glycolytic pathway enzyme present in the cytoplasm of eukaryotic cells and in some microorganisms. In human cells, it is also a component of cell surface membranes, where it functions as a human plasminogen receptor. The study aimed to purify Salmonella enterica serovar Typhimurium cytosolic enolase and obtain the antibodies against this protein; to identify enolase on the surface of bacteria; and to find cross-reactivity and plasminogen binding properties. Cytosolic enolase from S. Typhimurium was purified using a five-step preparation method. Anti-cytosolic enolase antibodies combined with scanning electron microscopy (SEM) allowed us to detect enolase on the surface of intact S. Typhimurium cells. The binding of plasminogen to surface enolase and the cross-reactivity of this protein with antibodies against human enolases were tested with western blot. Antibodies against human α- and β-enolases cross-reacted with S. Typhimurium membrane protein, the identity of which was further confirmed using a mass spectrometry analysis of enolase tryptic peptides. The enolase form bacterial membrane also bound plasminogen. The cross-reactivity of membrane enolase with antibodies against human enolases suggests that this bacterium shares epitopes with human proteins. Surface exposition of enolase and the demonstrated affinity for human plasminogen indicates that Salmonella membrane enolase could play a role in the interaction of S. Typhimurium with host cells.

Sections du résumé

BACKGROUND BACKGROUND
Enolase is generally known as the glycolytic pathway enzyme present in the cytoplasm of eukaryotic cells and in some microorganisms. In human cells, it is also a component of cell surface membranes, where it functions as a human plasminogen receptor.
OBJECTIVES OBJECTIVE
The study aimed to purify Salmonella enterica serovar Typhimurium cytosolic enolase and obtain the antibodies against this protein; to identify enolase on the surface of bacteria; and to find cross-reactivity and plasminogen binding properties.
MATERIAL AND METHODS METHODS
Cytosolic enolase from S. Typhimurium was purified using a five-step preparation method. Anti-cytosolic enolase antibodies combined with scanning electron microscopy (SEM) allowed us to detect enolase on the surface of intact S. Typhimurium cells. The binding of plasminogen to surface enolase and the cross-reactivity of this protein with antibodies against human enolases were tested with western blot.
RESULTS RESULTS
Antibodies against human α- and β-enolases cross-reacted with S. Typhimurium membrane protein, the identity of which was further confirmed using a mass spectrometry analysis of enolase tryptic peptides. The enolase form bacterial membrane also bound plasminogen.
CONCLUSIONS CONCLUSIONS
The cross-reactivity of membrane enolase with antibodies against human enolases suggests that this bacterium shares epitopes with human proteins. Surface exposition of enolase and the demonstrated affinity for human plasminogen indicates that Salmonella membrane enolase could play a role in the interaction of S. Typhimurium with host cells.

Identifiants

pubmed: 33245853
doi: 10.17219/acem/128233
doi:

Substances chimiques

Carrier Proteins 0
Membrane Proteins 0
Plasminogen 9001-91-6
Phosphopyruvate Hydratase EC 4.2.1.11

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1433-1441

Auteurs

Paweł Serek (P)

Department of Medical Biochemistry, Wroclaw Medical University, Poland.

Iwona Bednarz-Misa (I)

Department of Medical Biochemistry, Wroclaw Medical University, Poland.

Jadwiga Pietkiewicz (J)

Department of Medical Biochemistry, Wroclaw Medical University, Poland.

Bartłomiej Dudek (B)

Department of Microbiology, Faculty of Biological Sciences, University of Wrocław, Poland.

Magdalena Mierzchała-Pasierb (M)

Department of Medical Biochemistry, Wroclaw Medical University, Poland.

Katarzyna Jermakow (K)

Department of Microbiology, Wroclaw Medical University, Poland.

Marek Drab (M)

Unit of Nano-Structural Bio-Interactions, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

Andrzej Gamian (A)

Department of Medical Biochemistry, Wroclaw Medical University, Poland.
Medical Microbiology Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH